Health Care · Pharmaceutical Preparations

SPRO Spero Therapeutics Inc SEC Filings & Insider Trading Activity 2026

company
CIK 170110864 filings

SPRO at a glance

Spero Therapeutics Inc (SPRO, SEC CIK 1701108) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Spero Therapeutics Inc (SPRO) reported revenue of $12.6 million (up 3292.5% from FY2024) and net income of $8.6 million. Diluted EPS was $0.15.
  • As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding Spero Therapeutics Inc (SPRO) shares worth $11.3 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Rajavelu Esther on November 9, 2026 of 40,851 shares at $1.04 per share.
  • In the last 90 days, SPRO insiders reported 0 open-market purchases ($0) and 1 open-market sale ($42K) on Form 4, a net sale of $42K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$12.6M
+3292.5% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$42K
13F holders
17 funds
$11.3M · −3 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New lead-candidate dependence: July 8, 2026 Innovent Agreement shifted focus to SP001, now the only clinical-stage candidate
  • Most material update: Utebzi FDA approval and SPR206/SPR720 termination increased reliance on SP001 development and GSK commercialization
  • Regulatory risk: May 2026 House draft report could bar FDA consideration of China-generated clinical data supporting SP001’s IND
  • Competitive risk: SP001 faces approved UPLIZNA and multiple IgG4-related disease candidates in development
  • Liquidity risk: $105.0 million HCRx Notes limit retained GSK proceeds to 35% after repayment terms

Management Discussion & Analysis

  • Quarterly revenue $0 vs $5.442M YoY, reflecting no grant or collaboration revenue
  • Net loss $44.278M vs $7.382M YoY, operating loss $41.913M vs $7.916M
  • Worst-performing line: grant revenue $0 vs $2.394M, collaboration revenue $0 vs $3.048M
  • Cash $107.9M; operating cash use $32.098M, financing provided $99.761M from milestone and royalty financing
  • SP001 Phase 2 IgG4-RD trial expected Q2 2027, subject to FDA IND clearance; funding projected into second half of 2029

AI summary of the SPRO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced by Spero Therapeutics
  • Press release contains the financial results and management commentary, furnished as Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • SP001 Phase 2 IgG4-RD study targeted for Q2 2027, establishing the company’s next major clinical catalyst
  • $107.9M cash at September 30, 2026, expected to fund operations into the second half of 2029
Filed Nov 10, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Patrick Vink resigned November 10 after 11 years, without reported disputes, creating a Class II board vacancy
  • William Ho appointed to fill the Class II seat, adding clinical development and immunotherapy expertise
Filed Oct 27, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • COO Timothy Keutzer retiring December 31, 2026 after 11 years with Spero Therapeutics
  • Transition consulting expected through approximately February 28, 2027, terminable on 15 days’ notice

AI summaries of SPRO 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SPRO

Don't miss the next SPRO filing

  • Alerts as it files. A push when SPRO files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SPRO, by share count.
  • Ask anything. An AI agent that reads every SPRO filing and answers with sources.

SPRO alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
HO WILLIAMANov 10, 2026-
Rajavelu EstherSellNov 9, 2026$1.04
Zack DebraAAug 3, 2026-
Zack DebraAAug 3, 2026-
Pottage John C JrAJun 23, 2026-
Pottage John C JrAJun 23, 2026-
THOMAS FRANK EAJun 23, 2026-
Deshpande MilindAJun 23, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$933K$371K$12.6M
Operating Income$21.5M-$73.4M$6.3M
Net Income$22.8M-$68.6M$8.6M
Op. Margin2302.4%-19773.9%50.2%
Net Margin2444.4%-18481.4%68.1%
Balance Sheet
Total Assets$182.4M$110.5M$68.9M
Equity$106.9M$46.1M$59.0M
ROE21.3%-148.7%14.5%
Per Share
EPS-$-1.27$0.15
Cash Flow
Operating CF-$33.0M-$23.4M-$12.6M

Source: XBRL data in Spero Therapeutics Inc (SPRO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SPRO share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SPRO shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202617$11.3M
Q2 202620$19.3M
Q1 202616$19.6M
Q4 202518$19.4M
Q3 202517$14.4M
Q2 202515$20.3M
Q1 202514$4.6M
Q4 202412$6.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 129 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SPRO filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
8-KNov 10, 2026Analysis-
4Nov 10, 2026--
4Nov 10, 2026--
8-KOct 27, 2026Analysis-
8-KAug 28, 2026Analysis-
8-KAug 12, 2026Analysis-
10-QAug 12, 2026-
4Aug 6, 2026--
8-KJul 14, 2026Analysis-
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
8-KJun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
4Jun 25, 2026--
8-KJun 22, 2026--
10-QMay 13, 2026-
8-KMay 13, 2026-
4May 6, 2026-
8-KMar 26, 2026--
10-KMar 26, 2026-

Related Health Care companies

All Health Care →

SPRO SEC filings: frequently asked questions

Are SPRO insiders buying or selling?

In the last 90 days, Spero Therapeutics Inc (SPRO) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $42,485 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold SPRO stock?

As of September 30, 2026, the largest Spero Therapeutics Inc (SPRO) holders among the 13F filers tracked by SignalX were Pfizer Inc ($2.9 million), Vanguard Capital Management LLC ($2.5 million), Renaissance Technologies LLC ($1.7 million), Raymond James Financial ($914,000), Citadel Advisors LLC ($878,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was SPRO's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Spero Therapeutics Inc (SPRO) reported revenue of $12.6 million (up 3292.5% from FY2024) and net income of $8.6 million. Diluted EPS was $0.15. The figures come from the XBRL data in the 10-K.

What did SPRO report in its latest 8-K?

Spero Therapeutics Inc (SPRO) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Third-quarter results for period ended September 30, 2026 announced by Spero Therapeutics.

What are the latest SPRO SEC filings?

Spero Therapeutics Inc (SPRO) filed its latest 10-K annual report on March 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 10, 2026.

What is SPRO's SEC CIK number?

Spero Therapeutics Inc (SPRO)'s SEC Central Index Key (CIK) is 1701108. EDGAR lists every SPRO filing under that number.

Ask anything about SPRO

The research agent reads SPRO's filings, financials, insider trades and 13F holders, then answers with sources.